Man Group PLC Zai Lab LTD Transaction History

Man Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$22.28 - $38.71 $326,045 - $566,482	14,634 Added 9.4%	170,244 $5.23 Million
Q3 2022 Nov 14, 2022	SELL	$34.2 - $51.69 $3.99 Million - $6.03 Million	-116,648 Reduced 42.84%	155,610 $5.32 Million
Q2 2022 Aug 15, 2022	BUY	$23.14 - $49.68 $6.3 Million - $13.5 Million	272,258 New	272,258 $9.44 Million
Q4 2018 Feb 14, 2019	SELL	$14.95 - $24.72 $448,500 - $741,600	-30,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$17.8 - $25.35 $534,000 - $760,500	30,000 New	30,000 $585,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.57B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.